pirfenidone has been researched along with Cardiomegaly in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Cao, Q; Chen, Z; Huang, X; Lai, H; Ouyang, X; Tao, Y; Wang, S; Wang, Y; Yang, L; Zhou, H | 1 |
Gao, Y; Han, R; He, J; Kang, L; Li, C; Li, Y; Tian, J; Wang, J | 1 |
Hanatani, A; Iwao, H; Izumi, Y; Muro, T; Nakamura, Y; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
3 other study(ies) available for pirfenidone and Cardiomegaly
Article | Year |
---|---|
Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway.
Topics: Animals; Cardiomegaly; Isoproterenol; Mice; Myocytes, Cardiac; Pyridones; Signal Transduction; STAT3 Transcription Factor; TYK2 Kinase; Tyrosine | 2022 |
Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.
Topics: Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Collagen Type III; Feedback, Physiological; Fibrosis; Hemodynamics; Hydroxyproline; Liver X Receptors; Male; Myocardial Infarction; Myocardium; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyridones; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Signal Transduction; Systole; Ventricular Dysfunction | 2017 |
The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Cardiomegaly; Fibrosis; Heart; Heart Rate; Hypertension; Male; Mice; Mice, Inbred BALB C; Myocardium; Pyridones | 2012 |